Stryker Co. (NYSE:SYK) Shares Purchased by Waldron Private Wealth LLC

Waldron Private Wealth LLC raised its stake in shares of Stryker Co. (NYSE:SYK) by 0.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 73,622 shares of the medical technology company’s stock after buying an additional 192 shares during the quarter. Stryker comprises about 1.1% of Waldron Private Wealth LLC’s investment portfolio, making the stock its 19th biggest position. Waldron Private Wealth LLC’s holdings in Stryker were worth $25,050,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Precision Wealth Strategies LLC boosted its holdings in Stryker by 2.1% in the fourth quarter. Precision Wealth Strategies LLC now owns 3,114 shares of the medical technology company’s stock valued at $933,000 after acquiring an additional 65 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in Stryker by 2.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 169,527 shares of the medical technology company’s stock valued at $50,767,000 after acquiring an additional 3,632 shares during the last quarter. M&T Bank Corp boosted its holdings in Stryker by 0.3% in the fourth quarter. M&T Bank Corp now owns 49,597 shares of the medical technology company’s stock valued at $14,852,000 after acquiring an additional 168 shares during the last quarter. U.S. Capital Wealth Advisors LLC boosted its holdings in Stryker by 3.8% in the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 4,950 shares of the medical technology company’s stock valued at $1,482,000 after acquiring an additional 183 shares during the last quarter. Finally, Axxcess Wealth Management LLC raised its position in Stryker by 296.1% in the fourth quarter. Axxcess Wealth Management LLC now owns 4,931 shares of the medical technology company’s stock valued at $1,477,000 after purchasing an additional 3,686 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on SYK. Stifel Nicolaus cut their price objective on Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Barclays raised their price objective on Stryker from $374.00 to $402.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $386.00 target price on shares of Stryker in a research report on Wednesday, July 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research report on Thursday, July 11th. Finally, Needham & Company LLC lifted their target price on Stryker from $392.00 to $393.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $373.84.

Insider Transactions at Stryker

In other news, CFO Glenn S. Boehnlein sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the completion of the transaction, the chief financial officer now directly owns 2,852 shares in the company, valued at $949,716. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Glenn S. Boehnlein sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the sale, the chief financial officer now owns 2,852 shares of the company’s stock, valued at $949,716. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 190,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $323.46, for a total value of $61,457,400.00. Following the sale, the director now directly owns 3,316,608 shares in the company, valued at approximately $1,072,790,023.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 210,600 shares of company stock worth $68,330,400. Company insiders own 5.90% of the company’s stock.

Stryker Stock Performance

SYK stock traded up $2.49 during midday trading on Friday, reaching $360.42. The company had a trading volume of 1,307,583 shares, compared to its average volume of 1,185,878. The company has a quick ratio of 0.95, a current ratio of 1.68 and a debt-to-equity ratio of 0.51. The stock has a 50 day moving average price of $337.13 and a 200 day moving average price of $341.57. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The firm has a market capitalization of $137.35 billion, a PE ratio of 41.14, a P/E/G ratio of 2.78 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. The company had revenue of $5.42 billion during the quarter, compared to the consensus estimate of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. Stryker’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.54 earnings per share. Analysts anticipate that Stryker Co. will post 12 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be given a dividend of $0.80 per share. The ex-dividend date is Monday, September 30th. This represents a $3.20 annualized dividend and a dividend yield of 0.89%. Stryker’s dividend payout ratio is presently 36.53%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.